Peptide Purgatory: Let’s All Take GLP-1s

This week, we further observe Big Pharma’s unfettered market expansion of GLP-1 drugs into all aspects of our daily lives. Pretty soon, there’ll be GLP-1 fuel additives for your car and maybe a GLP-1 drywall joint compound — pricey, but will work wonders for fuel economy and a smooth drywall job. (Your house is getting a little chubby, too — admit it!) But on the medical front page today, we learn that GLP-1s are just what the doctor ordered for your sanity. You can’t make this shit up!

We’ll wrap up the week with Bullshit Corner, where we cast a cynically humorous eye on the anthropological side of GLP-1 receptor agonists.

So, buckle your seatbelts… Nah, this won’t be a rough ride!

---

GLP-1s: Now Treating Your Demons, Your Addictions, and Possibly Your Sump Pump

There was a time, not that long ago, when GLP-1 receptor agonists were modest little diabetes drugs. They lowered glucose, slowed gastric emptying, nudged insulin along, and stayed politely in their lane.

That era is over.

According to the latest breathless reporting from Healio, GLP-1s now appear poised to cure addiction, depression, dementia, suicidality, and whatever is rattling around in the human psyche that still lacks a billing code. I am only mildly surprised they stopped short of claiming improved marital harmony and leak-free basements.

Let’s be clear: there is real biology here. GLP-1 receptors exist in the brain. They intersect with dopamine pathways, reward circuits, the HPA axis, inflammation, and neurogenesis. None of that is crackpot science. The brain-gut axis is real, and anyone pretending otherwise is still stuck in a 1997 endocrinology textbook.

But what we are witnessing now is something else entirely: therapeutic scope creep fueled by marketing gravity.

The Addiction Angle: Interesting, Preliminary, and Already Overhyped

Animal models. Retrospective database analyses. Small human trials. Signals suggesting reduced alcohol cravings, fewer opioid overdoses, less nicotine use. All genuinely interesting.

Also: not remotely sufficient to declare GLP-1s the pharmacologic equivalent of Alcoholics Anonymous, cognitive behavioral therapy, and social support rolled into one weekly injection.

Even the psychiatrists quoted in the piece quietly wave the yellow flag, warning that substance use disorders are heterogeneous, messy, and stubbornly resistant to single-target pharmacology. Translation: anyone selling this as a universal addiction cure is either naïve or has a sales quota.

Depression and Mood: Correlation Is Not Redemption

Weight loss improves mood. Improved glycemic control improves energy. Reduced inflammation improves… a lot of things. None of that requires a revolutionary psychopharmacologic explanation.

Yet here we are, floating phrases like “mood stabilization” and “direct CNS effects” as though we’ve just reinvented SSRIs, minus the decades of trials and inconvenient side-effect disclosures.

The fact that one study hints at reduced suicidality while another hints at increased suicidal ideation should probably inspire caution, not a victory lap. The FDA’s “we found no association” is not the same thing as “problem solved.”

Cognition and Dementia: Hopeful, but Calm Down

Yes, GLP-1s may reduce neuroinflammation. Yes, hippocampal neurogenesis is intriguing. Yes, observational data suggest lower Alzheimer’s diagnoses in diabetics on semaglutide.

No, this does not mean we have stumbled upon a dementia-preventing fountain of youth that just happens to retail for $1,000 a month and is intermittently unavailable at CVS.

Even the Alzheimer’s Association is telling people, politely but firmly, do not ask your doctor for this. Which in modern medicine is roughly equivalent to shouting into a hurricane.

The Pattern Is the Problem

This is the same arc we’ve seen before:

1. Legitimate metabolic drug
2. Off-label curiosity
3. Epidemiologic signal
4. Media amplification
5. Pharma-funded trials “exploring potential benefits”
6. Influencers declaring victory
7. Insurance premiums quietly rising in the background

At some point, someone will seriously propose GLP-1s for “subclinical dissatisfaction with life,” and a white paper will be commissioned.

Final Thought Before We Start Fluoridating with Tirzepatide

GLP-1 receptor agonists are powerful drugs. They work because metabolism is foundational to human physiology. When you touch energy balance, inflammation, insulin signaling, and reward pathways, ripple effects are inevitable.

But inevitable effects are not the same as universal cures.

The danger here is not that GLP-1s are doing too much. It’s that we’re asking them to do everything, because medicine desperately wants a clean, injectable solution to problems that are messy, social, psychological, and structural.

If this keeps up, the next Healio headline will read:

“GLP-1s Show Promise in Treating Existential Malaise; Trials Ongoing.”

And honestly, at that point, I might sign up.

---

BULLSHIT CORNER™

The Moral Economy of Being Thin Enough

In the latest Perspective from the journal Obesity, a team of social scientists steps into what they call “uncharted territory”: the alarming discovery that people without obesity are using GLP-1 drugs to lose weight on purpose.

This is framed as more than off-label prescribing. It is a sociomedical event. GLP-1 receptor agonists, we are told, have escaped the clinic and entered the realm of “body optimization,” “pharmacological thinness,” and participation in a “moral economy of the body.” Slimness is not merely an outcome. It is a performative achievement signaling virtue, discipline, and social worth.

That is an impressively long way of saying: people like being thinner because the world treats them better when they are. The paper is not wrong about stigma. It just treats the drug as though it invented the stigma, rather than merely exposing it.

Much of the article is a large table of questions (not answers) about whether users feel guilt, shame, anxiety, dependence, or fear weight regain more than side effects. All fair questions. But the breathless tone suggests that the sin is not risk, but using a medical tool for a social problem.

Health: acceptable.
Diabetes: commendable.
Obesity: legitimate.
Wanting to look better, feel better, avoid stigma, or maintain weight: cue the emergency meeting.

The authors also roll out an intersectional, multinational lens (Brazil, the U.S., Japan, Denmark) to show that motives and meanings vary by culture. Interesting anthropology, sure. But it is not evidence that off-label GLP-1 use is inherently pathological. It is evidence that human beings are social animals trapped in status games, and bodies are the scoreboard.

The unspoken hum under every paragraph is this: if thinness becomes pharmacologically accessible, the moral hierarchy of bodies collapses. And that unsettles people who have built whole narratives around why thinness must be earned through suffering, or why it must remain unattainable to preserve the virtue structure.

Bullshit Corner verdict: insightful sociology, zero bedside guidance, and a faint whiff of resentment that the peasants found the cheat codes. GLP-1s did not create weight stigma or beauty standards. They just made weight change easier, and in doing so, stripped away some of the mythology that legitimacy requires misery.

Source: “The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective” (Obesity, published November 12, 2025).

---

Peptide Purgatory chronicles one old fart’s ongoing experiment with GLP-1s, metabolism, and medical modernity. Side effects may include sarcasm, elevated skepticism, and mild tachycardia while reading policy papers. So, ask your doctor whether Peptide Purgatory is right for you!

For an annotated catalog of all my Peptide Purgatory and Mounjaro updates, visit my Mounjaro Update Catalog page.